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Abstract
Background—Patients with inflammatory bowel disease (IBD) on certain immunosuppressants
have increased herpes zoster (HZ) risk.
Aim—To determine the risk of HZ in IBD and how anti-tumor necrosis factor-alpha (anti-
TNF)agents affect this risk.
Methods—We performed a retrospective cohort and nested case-control study using
administrative data from IMS LifeLink® Information Assets-Health Plan Claims Database. In the
cohort, we identified IBD patients < age 64 by diagnosis codes; matched to 4 individuals without
IBD. HZ risk was evaluated by incidence rate ratio (IRR) and adjusted Cox proportional hazards
models (HR). In the nested case-control analysis, 2,659 IBD patients with HZ were each matched
to 4 IBD patients without HZ. We determined associations between medications and HZ using
conditional logistic regression.
Results—The cohort included 50,932 patients with Crohn’s disease (CD), 56,403 patients with
ulcerative colitis (UC), and 1,269 with unspecified IBD, matched to 434,416 individuals without
IBD. The IBD cohort had increased HZ risk compared to non-IBD (IRR 1.68, 95% CI 1.60-1.76).
After adjustment, IBD patients had a higher risk of HZ than non-IBD (HR 1.49, 95% CI
1.42-1.57). In the nested case-control multivariate adjusted analyses, anti-TNF medications (OR
1.81, 95% CI 1.48-2.21), corticosteroids (OR 1.73, 95% CI 1.51-1.99) and thiopurines (OR 1.85,
95% CI 1.61-2.13) were independently associated with HZ. Risk of HZ was highest with
combination anti-TNF and thiopurine therapy (OR 3.29, 95% CI 2.33-4.65).
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Conclusions—Patients with IBD are at increased risk for HZ. Use of thiopurines, anti-TNF
agents, combination therapy, and corticosteroids increases HZ risk.
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Introduction
Herpes zoster (HZ) infection, also known as shingles, is associated with significant
morbidity and substantial costs. There are close to a million incident cases in the United
States (US) each year.1 Infection causes a painful, blistering rash usually isolated to one or
adjoining dermatomes. In approximately 10-18% of cases, post-herpetic neuralgia (PHN)
occurs.2 This pain syndrome can last from months to years after the initial HZ rash, without
very effective treatments. Other complications that can arise include bacterial skin infection,
ocular complications, motor neuropathy and meningitis. HZ is caused by reactivation of
latent varicella zoster virus (VZV), the virus that causes varicella (chicken pox). The
incidence of HZ in the United States (US) has been increasing over the past decade, and
significantly increases with age.3 It is estimated that the direct medical burden of HZ
infection is $1000 US dollars per patient, with costs doubling for those who are
immunosuppressed and quadrupling for those with PHN. This equates to greater than 1
billion dollars annually attributed to HZ in the US.4
Risk factors for HZ infection primarily include increasing age and immunosuppression.
Patients with inflammatory bowel disease (IBD) are one chronic disease population who
routinely use immunosuppressive medications including corticosteroids, thiopurines,
biologic anti-tumor necrosis factor alpha (anti-TNF) agents, and calcineurin inhibitors, and
therefore may be at increased risk for HZ. In a prior study by US researchers using data
from the United Kingdom (UK), Gupta et al showed an increased risk of HZ among
individuals with IBD as compared to the general population. Additionally, they found that
corticosteroids and thiopurines were risk factors for HZ in the IBD population.5 Data on
biologic anti-TNF medications were not available. More recently, Zhang et al showed a 1.2-
to 2.0-fold greater risk of HZ associated with corticosteroid use, including those also on
therapy with anti-TNF agents, in the older (≥ age 60) population with autoimmune
conditions such as rheumatoid arthritis (RA) or IBD.6
Biologic anti-TNF medications, particularly the monoclonal antibodies, have been
associated with an increased risk of HZ in the RA population.7-9 To further evaluate these
associations in the IBD population, we aimed to determine the risk of HZ in patients with
IBD as compared to a non-IBD cohort in the United States. We also aimed to determine
whether specific immunosuppressive medications, including biologic anti-TNF agents,
increase the risk of HZ in patients with IBD.
Methods
We analyzed the procedural and retail pharmacy claims covered by insurers contained in
IMS LifeLink® Information Assets-Health Plan Claims Database (a unit of IMS,
Watertown, MA. Copyright 2009, All Rights Reserved), for the period January 1, 1997
through December 31, 2009. This longitudinal, patient-level database has been used in
previous epidemiologic studies of IBD.10-12 At the time of the extraction, the source
database contained enrollment information on over 60 million persons from over 98 health
plans across the U.S. The included health care plans capture a geographically diverse sample
from across the United States. Prior studies have reported the IMS Health database to be
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representative of the national commercially insured population on a variety of demographic
measures, including geographic region, age, gender, and health plan type.13
Study Design
We performed a retrospective cohort study to determine the overall risk of herpes zoster in
IBD patients compared with a non-IBD cohort and a nested case-control study to determine
the independent effects of medication use (immunosuppressive, biologic anti-TNF therapy
and corticosteroids) on zoster risk among patients with IBD. A similar design has previously
been used by our group10, 12 and also by Gupta et al5 to evaluate the incidence of disorders
in patients with IBD and the effects of various medications.
Cohort Study
Patient selection—All patients aged <64 years with at least 12 months of continuous
health plan enrollment were eligible for inclusion in this analysis. We chose 64 as the upper
age limit to avoid the possibility of missing data resulting from Medicare dual eligibility
(which begins at age 65). Individuals were also required to have ongoing pharmacy
coverage with their health plan in order to fully capture medication exposures. We identified
cases of Crohn’s disease (CD) and ulcerative colitis (UC) using a previously reported
administrative definition expanded to include updated medications recently approved for
IBD indications.14 The precise definition included patients with at least 3 health care
contacts, on different days, associated with an International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9) diagnosis code for CD (555.xx) or UC (556.xx), or
patients with at least 1 claim for CD or UC and at least 1 pharmacy claim for any of the
following medications: mesalamine, olsalazine, balsalazide, sulfasalazine, 6-
mercaptopurine, azathioprine, methotrexate, infliximab, adalimumab, certolizumab pegol,
natalizumab and enteral budesonide. We did not include corticosteroid use in the definition,
due to widespread use of these medications for other indications. For patients who had
claims for both CD and UC, disease assignment was made according to the majority of the
last 9 claims or the majority of total claims if there were fewer than 9. If there were equal
numbers of claims for CD and UC, the individuals were classified as IBD-unspecified. We
matched each IBD patient to 4 non-IBD subjects by age, gender, and U.S. census region.
Region of the country was defined by standard regional definitions from the United States
Census Bureau. All individuals with any ICD-9 code for human immunodeficiency virus
(HIV) (042-044.9) were excluded related to differences in susceptibility to infections from
inherent immune dysfunction.
Cohort lead time and follow-up—Each cohort member was required to have a
minimum of 6 months of health plan enrollment prior to cohort entry. This “screening
period” was used to assess potential confounders of interest, particularly health care
utilization and cormorbidities. Each member of cohort was followed until the first diagnosis
of zoster, or, if none, until censoring at the earlier of one of two events: discontinuation of
primary or pharmacy insurance coverage, or age > 64.
Assessment of outcome (zoster)—Herpes zoster was defined as any 1 ICD-9 code for
herpes zoster (053.xx). This definition has been used previously to study zoster infection in
IBD.5 Additionally, this definition has been used to determine the incidence of zoster
infection in various other administrative databases in the United States.3, 15 This definition
has been validated, and has been found to have a sensitivity of 98% and a positive predictive
value of 93%.16 In a separate validation, ICD-9 code 053.xx for HZ correlated extremely
well with HZ diagnosis from chart review (kappa=0.92).9 No medications were used in the
definition of zoster, as antiviral agents are not uniformly prescribed. Anti-viral agents are
only recommended when the zoster diagnosis is made within 48-72 hours of the onset of the
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blistering rash. Prior studies have demonstrated that only 2/3 of individuals with zoster are
treated with anti-viral agents.9
Assessment of exposures—All exposure assessment occurred during the 6 month
“screening period”prior to cohort entry. Health care utilization was estimated in a
continuous fashion by the total of days with at least one health care contact over the time
period. Utilization has been measured in this fashion in prior pharmacoepidemiology
studies.17 Comorbidities were assessed using the Quan update18 of the validated Deyo
comorbidity index for administrative data.19 Medications, including corticosteroids,
immunomodulators, biologic anti-TNF agents, and 5-aminosalicylic acid (5-ASA) agents,
were assessed in the exposure period in an any/none fashion.
Statistical analysis—We used descriptive statistics to summarize characteristics of
patients with and without IBD. Continuous variables are reported as mean +/-standard
deviation or median and interquartile range (IQR), and categorical variables are reported as
percentages. We then calculated incidence rates of zoster (per 100,000 person-years) and
used incidence rate ratios (IRRs) and 95% confidence intervals (CIs) to compare the
incidence of zoster in IBD and non-IBD patients. We also performed subsequent analyses,
stratifying by age (in decades), and disease type (UC versus CD). We assessed for possible
violation of the proportional hazards assumption via log-log plots. As the assumption was
not violated, we used Cox proportional hazards models to calculate hazard ratios (HRs) and
95% CIs for the risk of zoster in the IBD cohort as compared to the non-IBD cohort,
controlling for health care utilization and comorbidities. Analyses were repeated stratified
by CD versus UC.
Nested Case-Control Study
We next conducted a case-control study evaluating the association between corticosteroids,
immunosuppressive or biologic anti-TNF medication use and zoster. This study was nested
within the previously defined cohort of patients with IBD.
Selection of cases and controls—Cases were those IBD patients who were diagnosed
with zoster, and controls were those IBD patients without zoster. Each case patient was
matched on gender, age, geographic region, disease type (CD or UC), and duration of
follow-up to 4 IBD patients who did not have zoster using incidence density sampling. In
this sampling technique, a case patient can also be a control patient, provided that the case
patient has not yet been diagnosed with zoster (has not yet become a case) at the time he or
she is selected as a control. Once a case is diagnosed with zoster, he or she is no longer
eligible to become a control, or a case again. A total of 257 patients were included as both
cases and controls.
Assessment of outcome (zoster)—The outcome was herpes zoster infection, as
defined within the cohort study by ICD-9 code (053.xx). This definition has been validated
in other populations, with appropriate sensitivity, specificity, and concordance with medical
records.9, 16
Assessment of exposures
Medication Use: The primary medications evaluated included azathioprine and 6-
mercaptopurine (thiopurine class), methotrexate, tacrolimus and cyclosporine (calcineurin
class), infliximab, adalimumab, and certolizumab pegol (biologic anti-TNF class) and
systemic corticosteroids. Medication exposures were analyzed with respect to the amount of
time preceding the diagnosis of zoster in cases or the corresponding index date in controls.
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All exposures were defined as at least 1 outpatient pharmacy claim occurring during the 120
days prior to zoster diagnosis.
Potential confounders: Data on utilization and comorbidities were also included as
exposure variables in the case-control study. These variables were assessed during the 6
month exposure period prior to zoster diagnosis. Utilization was defined in a continuous
fashion as total number of days with at least one health care contact. Comorbidities were
assessed through the Quan update18 of the validated Deyo comorbidity index19 for
administrative claims data.
Statistical analysis—Characteristics of cases and controls were described using
descriptive statistics. We then used conditional logistic regression to calculate odds ratios
(ORs) and 95% CIs for each medication exposure related to the outcome of zoster. We
constructed a full model by using all potential confounders and eliminated these
confounders via a backwards elimination strategy by using a change in estimate approach
(threshold of <10% change). Analyses were performed for patients with IBD and also
stratified by UC and CD diagnosis.
For all analyses, p values were two-sided, and a p value of .05 or less was considered
statistically significant. All statistical analyses were performed using Stata version 11.0
(College Station, TX). The study protocol was granted exemption from review by the
Institutional Review Board at University of North Carolina because it involved the use of
existing, de-identified data.
Results
The cohort study population included 108,604 patients with IBD. Of these, 50,932 had CD,
56403 had UC and 1,269 had IBD with unknown type. The patients with IBD contributed a
total of 364,533 person-years of observation time to the cohort. There were a total of
434,416 individuals in the non-IBD comparison cohort. The non-IBD patients contributed a
total of 992,273 person-years of observation time to the cohort. The median length of follow
up within the non-IBD cohort was 24 months (IQR 12-42) with a range from 1-138 months
after the 6 month “screening” period. Length of follow-up was similar for CD (34 months,
IQR 19-51) and UC populations (36 months, IQR 21-54). Duration of follow-up was
significantly less in the non-IBD comparison cohort (21 months, IQR 10-38). Table 1 shows
the characteristics of the IBD cohort as compared to the non-IBD cohort. The IBD cohort
had increased health care utilization, and immunosuppressive medication use as compared to
the matched non-IBD cohort, as expected. These same factors were increased in those with
CD as compared to those with UC.
In the IBD population, there were a total of 2677 cases of zoster. In the non-IBD population,
there were a total of 4340 cases of zoster. For patients with IBD, the overall annual
incidence of HZ was 734/100,000 (95% CI 707/100,000-763/100,000), compared to
437/100,000 (95% CI 424/100,000-451/100,000) in the non-IBD cohort (incidence rate ratio
[IRR] 1.68, 95% CI 1.60-1.76). The incidence of zoster in CD was somewhat higher than
that in UC (figure 1). The IBD cohort had an increased zoster risk when compared to non-
IBD (IRR 1.68, 95% CI 1.60-1.76), as did CD versus non-CD (IRR 1.91, 95% CI 1.78-2.05)
and UC versus non-UC (IRR 1.50, 95% CI 1.40-1.61). The incidence of HZ was then
evaluated in strata of age, with increasing incidence of zoster within each strata of age, for
both IBD and non-IBD populations. The highest incidence was in the 60+ age strata for
those with CD (1502/100,000, 95% CI 1236/100,000-1809/100,000), as expected (figure 2).
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After adjusting for comorbidities and health care utilization on Cox analysis, zoster risk
remained increased in the IBD versus non-IBD cohort (HR 1.49, 95% CI 1.42-1.57). Risk
was particularly increased risk for those with CD as compared to non-CD (HR 1.69, 95% CI
1.58-1.82). For UC, the adjusted risk compared to non-UC was HR 1.34, 95% CI 1.25-1.44.
In the nested case control study, 2,659 IBD patients with HZ were matched to 10,470 IBD
patients without HZ. A total of 18 IBD patients with zoster were unable to be matched to a
comparison IBD patient without zoster. The characteristics of the populations are shown in
table 2. Patients with HZ had significantly more comorbidities, including cardiac conditions,
diabetes, liver disease, renal disease and chronic pulmonary disease. Those with HZ also had
significantly higher health care utilization and immunosuppressive medication use. In
adjusted analyses, 5-ASA use was not associated with HZ in the overall IBD population (OR
1.08, 95% CI 0.97-1.19). However, thiopurine use (OR 1.85, 95% CI 1.61-2.13),
corticosteroid use (OR 1.73, 95% CI 1.51-1.99), and biologic anti-TNF use (OR 1.81, 95%
CI 1.48-2.21) were independently associated with HZ in the overall IBD population. Similar
risk estimates were seen when stratified by CD or UC. Crude and adjusted analyses are
shown in table 3 for specific medication use in the overall population, and by IBD subtype.
In a sub-analysis, we then investigated combination use of anti-TNF and thiopurine and
monotherapy of either agent as compared to no immunosuppressive medication use. Those
on combination therapy had the highest risk of zoster, even after controlling for
corticosteroid use, 5-ASA use, utilization and comorbidities (OR 3.29, 95% CI 2.33-4.65)
(table 4).
Discussion
Herpes zoster is an important cause of increased morbidity and mortality in the United
States, with approximately 1 million cases annually. Incidence of HZ in the general
population is 340/100,000, but is strongly affected by age, with the highest incidence in
those >80 years at 1100/100,000.20
The lifetime risk of developing HZ is approximately 30%. The course of the unilateral,
painful rash is generally 2-4 weeks. There can be significant complications from HZ
including: post-herpetic neuralgia, ophthalmologic, neurologic (encephalitis) and
dermatologic (secondary skin infection) involvement or complications. Understanding the
incidence and risk factors for HZ in an IBD population is important to guide prevention
efforts. As HZ is associated with substantial morbidity and costs,4 this emphasis upon
prevention is warranted.
In our large administrative study of HZ infection in IBD patients, we demonstrated a
significantly increased risk of HZ when compared to the general population; with
particularly increased risk among those on immunosuppression. As with the general
population, we showed increasing HZ risk with advancing age. The etiology of the increased
HZ risk in IBD is likely multifactorial; immunosuppressive medications, age-related
changes in immune function and the innate immune dysregulation associated with IBD
itself.
Other populations receiving immunosuppression are also at increased risk for HZ. For
example, in individuals with RA, the incidence of HZ has been found to be 996 per 100,000
patient-years. Risk factors for HZ in this population of Veterans included advancing age,
corticosteroid use, immunosuppressive medications used in moderate RA (such as
thiopurines, calcineurin inhibitors or methotrexate) and severe RA (biologic anti-TNF
agents), malignancy, and comorbid conditions such as chronic lung disease, renal failure or
liver disease.9 A separate study of anti-TNF use in RA patients found increased risk
Long et al. Page 6













associated with the monoclonal anti-TNF antibodies (HR 1.82, 95% CI, 1.05-3.15).7
Increased risk has also been demonstrated in the solid organ transplant (SOT) population.
The incidence of HZ is 2222 per 100,000 person-years in the SOT population, with
increasing risk associated with increasing levels of immunosuppression (the highest absolute
risk is among heart transplant recipients) and increasing age.21
The IBD population has been previously shown to have an increased risk of HZ. Gupta et al
evaluated data from the UK and found an increased relative risk of HZ for both CD and UC
(IRR 1.61, 95% CI 1.35-1.92 and IRR 1.21, 95% CI 1.05-1.40 respectively).5 We found
similar risks in our population, with unadjusted IRRs of 1.9 for CD and 1.5 for UC. Similar
to Gupta et al, we found increasing risk with advancing age. The overall incidence in our
population was 734/100,000 (95% CI 707/100,000-763/100,000) person-years, and overall
age-specific risks in 10 year strata were similar to those risks found by Gupta et al. We also
found an increased risk of HZ associated with increasing numbers of comorbidities, as has
been reported in the other populations.9 In a recent study by Zhang et al of older individuals
(age ≥60 years) with autoimmune conditions such as RA or IBD, the incidence of HZ in
those with prior shingles vaccination was 780/100,000 and 1160/100,000 in those not
previously receiving vaccination.6 These effect estimates are slightly higher than overall
estimates found in our study; but similar to those in our older age strata.
In our nested case-control study, we investigated the independent effects of various classes
of medications used in the treatment of IBD. We found that immunosuppressive
medications, including anti-TNF agents (OR 1.81, 95% CI 1.48-2.21), corticosteroids (OR
1.73, 95% CI 1.51-1.99) and thiopurines (OR 1.85, 95% CI 1.61-2.13) were each
independently associated with increased HZ risk. The study by Gupta et al pre-dated use of
anti-TNF agents, but did estimate the risk of corticosteroids and thiopurines in IBD. Their
adjusted odds ratio for corticosteroid use was OR 1.5, 95% CI, 1.1–2.2; whereas for
thiopurines, the risk was greater (adjusted odds ratio, 3.1; 95% CI, 1.7–5.6). We found
similar levels of increased risk, albeit somewhat lower for thiopurines. We found no risk
associated with 5-ASA use, which served as a negative control, demonstrating that the
mechanism of increased risk is driven by immunosuppression and/or severity of underlying
IBD. Finally, we investigated the risk associated with combination therapy (anti-TNF and
thiopurine), controlling for comorbidities, utilization and other medication use, and found
the highest overall odds ratio of 3.3. This demonstrates there are potentially additive risks of
HZ with >1 immunosuppressive agent.
There are strengths to this large study of HZ incidence and risk factors. Primarily, we
studied a very large and geographically diverse population from throughout the United
States. Due to this diversity, the sample is broadly generalizable to the commercially insured
US population. Secondly, we utilized complete data on all billed outpatient prescriptions in
order to capture medication exposures; without relying on patient recall. Third, were also
able to account for both health care utilization and potentially confounding comorbidities.
To do so, we used a validated comorbidity index for administrative data.18,19
There are also several limitations to this study that utilized administrative claims data. As
with all studies of claims data, there is the possibility of misclassification of exposure and
outcome related to the lack of clinical detail. However, we used an established IBD
exposure definition 10, 11 that requires multiple health contacts and/or IBD related
prescriptions. A similar, but even less specific, administrative case definition has been
validated by Herrinton et al with a sensitivity exceeding 90% and a PPV exceeding 80% for
overall IBD.22 We used an outcome definition of HZ consisting of any ICD-9 code (053.xx).
This administrative definition has been validated, with a sensitivity of 98% and a positive
predictive value of 93%.16 In a separate validation, ICD-9 code 053.xx for HZ correlated
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extremely well with HZ diagnosis from chart review (kappa=0.92).9 Additionally, as risk of
HZ is known to increase with age, it is a limitation that the elderly (>age 65) were not
represented in our population. This lack of older persons in our study population does not
affect the validity of the relative risks we presented in the context of the under 65
population. In spite of controlling for both health care utilization and comorbidities
(including malignancy) within our study, and excluding those with HIV, there are other
potential risk factors associated with HZ that may not have been accounted for. For
example, we were unable to capture race, and there are some data to suggest that age at
diagnosis of HZ may be associated with race.23 However, in order to be a confounder, a
factor must be associated with both the exposure and the outcome. Race may or may not be
associated with our exposures of IBD (in the cohort study) and immunosuppressive
medication use (in the nested case-control study). In fact, the incidence of IBD among
African Americans now approaches that of Caucasians in the US. Among studies that have
shown differences in immunosuppressive medication use by race,24 many quote access to
care and socioeconomic factors as a potential cause. In our study, all patients have health
insurance, thereby alleviating many of the socioeconomic factors. Finally, we could not
utilize the potentially ideal study design of a cohort study with time varying medication
exposures due to the inability to account for the precise timing of initiation and
discontinuation of medications. This is particularly true for corticosteroids which are often
written for use “as directed .” For this reason, we designed the nested-case control study and
accounted for any medication use over a 120 day window. We were also unable to assess the
role of the shingles vaccination in our population, as this vaccination is often not covered by
insurers in those <age 60, and our data do not extend beyond age 64 due to medicare dual
eligibility.
In conclusion, understanding the medication-specific risks of HZ is important, particularly
as practice patterns in IBD management change. For example, there is now an emphasis
upon early, aggressive management of CD. As biologic anti-TNF and other
immunosuppressant use in IBD becomes more prevalent, this increased utilization may
account for a further increase in the incidence of HZ. A new vaccine against varicella zoster
virus (shingles), Zostavax®, became commercially available in 2006. The vaccine contains
the same strain used in the varicella (chicken pox) vaccine, but is 14 times more potent. The
shingles vaccine is effective, decreasing zoster incidence by >50%. 25 This vaccine is
currently recommended by the Advisory Committee on Immunization Practices (ACIP) in
individuals ≥ age 60 without contraindications. 26 As the vaccine is live, it is contraindicated
in individuals already on immunosuppression (corticosteroids (≥20 mg/day for greater than
2 weeks), biologic anti-TNF agents, chemotherapy). In its most recent Guide to Vaccine
Contraindications and Precautions, the Centers for Disease Control (CDC) determined that
the vaccine could be offered to individuals on low doses of immunosuppression (defined as
methotrexate (≤0.4 mg/Kg/week), azathioprine (≤3.0 mg/Kg/day), or 6-mercaptopurine
(≤1.5 mg/Kg/day)).27 However, the ideal time to dose this vaccine may be prior to initiation
of immunosuppression. The vaccine has not specifically been tested in younger populations
or in populations with immune dysfunction such as IBD. Zhang et al recently found a
reduced incidence of HZ in older individuals (≥ age 60) with autoimmune conditions and
prior receipt of vaccination as compared to a similar group with no prior vaccination;
including those exposed to biologics.6 Importantly, overall rates of HZ vaccination in older
individuals with autoimmune conditions remain quite low; 1.2% in one US population.28
Therefore, this represents a potential missed opportunity for prevention. Future studies will
need to determine the role, safety and timing of this vaccination in patients of all ages with
IBD. As HZ and its complications are potentially preventable, optimizing the delivery and
timing of vaccination in IBD patients will be important in years to come.
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Annual Zoster Incidence (per 100,000) in Inflammatory Bowel Disease (IBD) (n=108,604)
and non-IBD Populations (n=434,416), Stratified by Crohn’s disease (CD) (n=50,932) as
Compared to non-CD (n=203,728) and Ulcerative Colitis (UC) (n=56,403) as Compared to
non-UC (n=225,612) Populations.
Footnote: Data from IMS LifeLink® Information Assets-Health Plan Claims Database
(1997-2009), IMS Health Incorporated.
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Annual Zoster Incidence (per 100,000) in Crohn’s disease (CD) (n=50,932) as Compared to
non-CD Populations (n=203,728) and Ulcerative Colitis (UC) (n=56,403) as Compared to
non-UC Populations (n=225,612), within 10 Year Strata of Age
Footnote: Data from IMS LifeLink® Information Assets-Health Plan Claims Database
(1997-2009), IMS Health Incorporated.
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